Navigation Links
Moffitt researchers find cancer therapies affect cognitive functioning among breast cancer survivors

Researchers at Moffitt Cancer Center and colleagues at the University of South Florida and University of Kentucky have found that breast cancer survivors who have had chemotherapy, radiation or both do not perform as well on some cognitive tests as women who have not had cancer.

They published their study in the April 1 issue of Cancer.

"Survivors of breast cancer are living longer, so there is a need to better understand the long-term effects of cancer therapies, such as chemotherapy and radiation," said study lead author Paul B. Jacobsen, Ph.D., associate center director for Population Sciences.

To carry out their study, the researchers recruited 313 women being treated by either chemotherapy or radiotherapy for early stage breast cancer at Moffitt Cancer Center and the University of Kentucky Chandler Medical Center. Those who had undergone treatment for cancer were tested six months after treatment and then tested again 36 months after having completed treatment.

They also recruited a control group of women who did not have cancer. These participants were also tested at six months and 36 months.

Participants in all groups were within five years of age, and breast cancer patients were matched with noncancer patients who lived in their same ZIP codes. Participants were tested cognitively with respect to processing speed (quick task completion under pressure), executive functioning (ability to shift cognitive sets and solve novel problems), the two domains expected to be most affected by chemotherapy. They were also tested with regard to verbal abilities.

"Our findings were partially consistent with prior research," explained Jacobsen. "We found that chemotherapy-treated patients performed worse than noncancer controls in processing speed, executive functioning and verbal ability. These domains may be the domains most affected by chemotherapy."

The also found test results for the radiotherapy group to be similar to the results of those in the chemotherapy group. Additionally, they discovered that the noncancer group improved in these cognitive abilities over time while the chemotherapy and radiotherapy groups did not. There were no differences in performance between the radiotherapy and chemotherapy groups, noted the researchers.

The researchers commented that they were fortunate for having included the radiotherapy groups because their results were so similar to the chemotherapy group. Had that group not been included, conclusions could have been drawn to suggest that the cognitive differences between the noncancer group and the chemotherapy group were specific to chemotherapy.

"Since patients report cognitive problems that interfere with their daily activities, early workups should include tests to determine cognitive functioning prior to treatment," concluded Jacobsen. "Future research also needs to investigate factors that may affect both chemotherapy patients and those receiving radiotherapy. Providers may wish to communicate that such effects can accompany chemotherapy and radiation therapy."


Contact: Patty Kim
H. Lee Moffitt Cancer Center & Research Institute

Related medicine news :

1. New Moffitt Cancer Center patent promises to accelerate cancer trials
2. Moffitt, Sanford-Burnham and Florida Hospital create Personalized Medicine Partnership of Florida
3. Fibroblasts contribute to melanoma tumor growth, say Moffitt Cancer Center researchers
4. Moffitt Cancer Center researchers find potential target for treating metastatic cancer
5. Moffitt researchers will be strong participants in American Society of Hematology meeting
6. Moffitt Cancer Center researchers find MK1775 active against sarcomas
7. Moffitt Cancer Center researchers find men less willing to be screened for cancer
8. Moffitt Cancer Center researchers unravel biochemical factor important in tumor metastasis
9. Moffitt Cancer Center researchers find regulatory T-cell clue to help prevent GVHD
10. Moffitt Cancer Center researchers find more clues to causes of breast cancer
11. Moffitt researchers find possible key to preventing chemotherapy resistance in ovarian cancer
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can now ... and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings ... The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited to ... Recovery® program to drive cancer patients to and from their cancer treatments. Comfort ... quality of life and ongoing independence. Getting to and from medical treatments is ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... June 23, 2016 Any dentist who has made ... the current process. Many of them do not even offer ... difficulties and high laboratory costs involved. And those who ARE ... at such a high cost that the majority of today,s ... Dr. Parsa Zadeh , founder of Dental Evolutions Inc. ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology: